1 / 4

Influenza Therapeutics Market- Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Influenza is a condition that causes contagious illness. It is characterized by sudden onset of fever, headache, sore throat, non-productive cough, and rhinitis.<br>

rajbisen
Download Presentation

Influenza Therapeutics Market- Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Therapeutics Market- Size, Share, Outlook, Influenza Therapeutics Market- Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026 and Opportunity Analysis, 2018 – 2026 Influenza is a condition that causes contagious illness. It is characterized by sudden onset of fever, headache, sore throat, non-productive cough, and rhinitis. Usually infection lasts for about a week. Over the course of a flu season, different types and subtypes of influenza can cause illness in humans. There are four types of influenza virus such as A, B, C, and D. Influenza A and B virus causes most of the illness in humans. Prolonged influenza infections can cause severe complications such as pneumonia, bronchitis, acute respiratory distress, secondary bacterial infections, and cardiovascular complications. To control the illness caused by influenza virus, influenza antiviral prescription drugs can be used. Request Sample Copy of Research Report @ Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2443 https://www.coherentmarketinsights.com/insight/request-sample/2443 Influenza Therapeutics Market: Drivers Influenza Therapeutics Market: Drivers New drug approvals for the treatment of influenza is expected to drive the influenza therapeutics market growth. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older. Increasing number of clinical pipeline studies is expected to boost the influenza therapeutics market growth during the forecast period. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad- spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April 2019. Influenza Therapeutics Market: Restraints Influenza Therapeutics Market: Restraints Influenza vaccines have several limitations including relatively long production times, limited vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, which is

  2. projected to restrain growth of the influenza therapeutic market during the forecast period. Moreover, increasing concerns among people about the side effects of vaccines hamper growth of the influenza therapeutic market. For instance, in October 2018, according to the National Opinion Research Centre (NORC) at the University of Chicago survey, around 43% of the adults were vaccinated and 14% plans to receive the flu shot. However, around 41% of the American people reported that they are not vaccinated and do not intend to get vaccinated, as adults were most likely to cite concerns about side effects of the vaccine. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Influenza Therapeutics Market Research Objective and Assumption • Influenza Therapeutics Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Influenza Therapeutics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Influenza Therapeutics Market, By Regions • Influenza Therapeutics Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Influenza Therapeutics Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Influenza Therapeutics Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Influenza Therapeutics Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion

  3. Influenza Therapeutics Market: Regional Analysis Influenza Therapeutics Market: Regional Analysis On the basis of region, the global influenza therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the market, owing to high presence of key players such as GlaxoSmithKline plc and Hoffmann-La Roche Ltd. The regulatory agencies in the region select influenza viruses that are required for developing the influenza vaccine. In March 2018, FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) conducted a meeting to select the influenza viruses for the composition of the influenza vaccine. In the meeting, VRBPAC recommended the trivalent formulation of influenza vaccines for influenza A including A/Michigan/45/2015 (H1N1) pdm09-like virus, A/Singapore/INFIMH-16–0019/2016 (H3N2)-like virus, and B/Colorado/06/2017-like virus (B/Victoria lineage). The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain: a B/Phuket/3073/2013-like virus (B/Yamagata lineage). Inquire Here Before Purchase of Research Report @ Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2443 https://www.coherentmarketinsights.com/insight/talk-to-analyst/2443 Asia Pacific is also expected to witness significant growth in the influenza therapeutics market, owing to increasing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI), to reduce the burden of influenza by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities. Europe have also gained significant position in the market, owing to increasing initiatives by European Medical Association (EMA) during an influenza pandemic season leading to continuous monitoring of safety of centrally authorized pandemic influenza vaccines and antiviral medicines, and fast-track review of data for the authorization of pandemic influenza vaccines for use in all EU Member States. Also, increasing number of public awareness programs for the prevention and diagnosis of influenza resulted in significant growth of the influenza therapeutics market in this region. Key players operating in the global influenza therapeutic market include Daiichi Sankyo Key players operating in the global influenza therapeutic market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc. Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.

  4. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related